DE69330390T2 - Hybride Proteinkomplexe, betreffendes Herstellungsverfahren, und ihre Anwendungen in der Diagnostik, als therapeutische Agens oder Reaktionsmittel, das in der Medizin Verwendung findet - Google Patents

Hybride Proteinkomplexe, betreffendes Herstellungsverfahren, und ihre Anwendungen in der Diagnostik, als therapeutische Agens oder Reaktionsmittel, das in der Medizin Verwendung findet

Info

Publication number
DE69330390T2
DE69330390T2 DE69330390T DE69330390T DE69330390T2 DE 69330390 T2 DE69330390 T2 DE 69330390T2 DE 69330390 T DE69330390 T DE 69330390T DE 69330390 T DE69330390 T DE 69330390T DE 69330390 T2 DE69330390 T2 DE 69330390T2
Authority
DE
Germany
Prior art keywords
applications
protein complexes
diagnostics
medicine
hybrid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330390T
Other languages
English (en)
Other versions
DE69330390D1 (de
Inventor
Jean-Claude Boulain
Frederic Ducancel
Daniel Gillet
Andre Menez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of DE69330390D1 publication Critical patent/DE69330390D1/de
Application granted granted Critical
Publication of DE69330390T2 publication Critical patent/DE69330390T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69330390T 1992-02-11 1993-02-09 Hybride Proteinkomplexe, betreffendes Herstellungsverfahren, und ihre Anwendungen in der Diagnostik, als therapeutische Agens oder Reaktionsmittel, das in der Medizin Verwendung findet Expired - Fee Related DE69330390T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201505A FR2687157B1 (fr) 1992-02-11 1992-02-11 Proteines hybrides complexes, leur procede de preparation, et leurs applications comme agent de diagnostic, comme agent a visee therapeutique ou comme reactif utilisable en imagerie medicale.

Publications (2)

Publication Number Publication Date
DE69330390D1 DE69330390D1 (de) 2001-08-09
DE69330390T2 true DE69330390T2 (de) 2002-10-17

Family

ID=9426518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330390T Expired - Fee Related DE69330390T2 (de) 1992-02-11 1993-02-09 Hybride Proteinkomplexe, betreffendes Herstellungsverfahren, und ihre Anwendungen in der Diagnostik, als therapeutische Agens oder Reaktionsmittel, das in der Medizin Verwendung findet

Country Status (6)

Country Link
EP (1) EP0556111B1 (de)
JP (1) JPH06277092A (de)
AT (1) ATE202799T1 (de)
CA (1) CA2089139A1 (de)
DE (1) DE69330390T2 (de)
FR (1) FR2687157B1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200732472A (en) * 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648713B1 (fr) * 1989-06-26 1994-06-10 Commissariat Energie Atomique Proteines hybrides entre une enzyme extracytoplasmique et une autre proteine, leur procede de preparation, ainsi que leur application comme agent de diagnostic

Also Published As

Publication number Publication date
DE69330390D1 (de) 2001-08-09
FR2687157B1 (fr) 1995-10-06
EP0556111A1 (de) 1993-08-18
CA2089139A1 (en) 1993-08-12
EP0556111B1 (de) 2001-07-04
JPH06277092A (ja) 1994-10-04
ATE202799T1 (de) 2001-07-15
FR2687157A1 (fr) 1993-08-13

Similar Documents

Publication Publication Date Title
Starfield et al. Effectiveness of pediatric care: the relationship between processes and outcome
Elton et al. Psychological control of pain.
ATE157990T1 (de) Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
ES2124209T3 (es) Anticuerpos monoclonales mejorados reactivos con caquectina.
DE69020007D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
DE3668704D1 (de) Fluoreszierende verbindungen und ihr biologischer diagnostischer zweck.
Montbriand An overview of alternate therapies chosen by patients with cancer
ATE123952T1 (de) Vernetzte antikörper und verfahren zu ihrer herstellung.
DE69330390D1 (de) Hybride Proteinkomplexe, betreffendes Herstellungsverfahren, und ihre Anwendungen in der Diagnostik, als therapeutische Agens oder Reaktionsmittel, das in der Medizin Verwendung findet
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
Ribeiro et al. Eosinophilic leukaemia with trisomy 8 and double gammopathy.
Awad et al. Diagnostic criteria as a predictor of drug response in schizophrenia.
Garvey et al. Changes in urinary MHPG during treatment of depression with imipramine.
FR2608431B1 (fr) Enceinte mobile de transport et de decontamination pour materiels radiologiques medicaux chirurgicaux ou de laboratoire ou autres
Hudson Vision of the future?
Pollack " Reports on my death are greatly exaggerated": The survival of psychoanalytic psychotherapy in national health care reform.
Heald Interferon and Hillary Clinton
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
of Appeal Barber v. Superior Court of State of California; Nejdl v. Superior Court of State of California
Myers When helping starts to hurt: A New Look at Burnout among Psychotherapists. WN Grosch and DC Olsen, New York: WW Norton & Co., 1994. Can $29.99
EP0453419A3 (en) Use of the sp-2 monoclonal antibody for diagnostics and for monitoring of the hiv infection progress
Court In re Estate of Longeway

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee